(0.07%) 5 472.98 points
(0.11%) 39 154 points
(0.38%) 17 784 points
(0.09%) $80.90
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.23%) $28.94
(3.64%) $1 022.30
(0.29%) $0.936
(0.69%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system...
Stats | |
---|---|
今日成交量 | 29 400 |
平均成交量 | 0 |
市值 | 13 069.00 |
EPS | $-0.830 ( Q3 | 2023-11-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Gorgas Gregory D. | Buy | 92 000 | Stock Option (right to buy) |
2023-08-04 | Matsui Connie | Buy | 1 083 | Stock Option (right to buy) |
2023-08-04 | Blayney Douglas | Buy | 1 083 | Stock Option (right to buy) |
2023-08-04 | Reyes Gregory | Buy | 1 083 | Stock Option (right to buy) |
2023-08-04 | Emanuele Robert Martin | Buy | 1 083 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 64 transactions |
Buy: 4 184 534 | Sell: 89 374 |
Artelo Biosciences, Inc. 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-3.49 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-3.49 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.19 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.995 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Artelo Biosciences, Inc.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。